PCSK9 inhibitors: From bench to bedside

10' education - Mar. 17, 2017 - Prof. Gilles Lambert – Sainte-Clotilde, France - ACC 2017, Washington DC, USA

PCSK9 Expert Opinions Prof. Gilles Lambert describes the development of PCSK9 inhibitors since the discovery in 2002 of PCSK9 as a circulating protein targeting the LDL receptor for degradation. Now in 2017, results of outcome trials with a PCSK9 inhibitor are available.

Video navigation menu

A long road since the discovery of PCSK9, a circulating protein targeting the LDL receptor for degradation 00:23
Cardiovascular benefits of PCSK9 loss of function mutations 02:22
Development of PCSK9 inhibitors 02:56
Lowering LDL-c and Lp(a) by inhibiting PCSK9 with mAbs 04:01
Results of PCSK9 outcome trials 05:18

Educational information

This educational video is part of a series of PCSK9 Expert Opinions that are aimed to provide different perspectives and opinions from international experts in this field and may provide support with the interpretation and translation of new findings towards implications for clinical practice

The educational content reflects the personal opinion of the experts and is recorded as an independent educational service by PACE-CME

Disclosures

Prof. Gilles Lambert – Université de la Réunion, Sainte-Clotilde, France

Funding

Funding was provided by an unrestricted educational grant from Amgen

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.